Drug intelligence / Profile preview

MDG3020

Development stage: Preclinical
Lead developer: EpimAb Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MDG3020 is an investigational T cell engager immunotherapy that combines Medigene's proprietary 3S (sensitivity, specificity, safety) T cell receptor (TCR) technology with EpimAb's proprietary CD3 antibody and FIT-Ig TCE platform. The drug is designed to redirect and activate a patient's own T cells to recognize and kill cancer cells by targeting specific tumor antigens. This approach aims to improve the efficacy, specificity, and safety of cancer immunotherapy by leveraging both advanced TCR engineering and bispecific antibody technology[1][2].

Targets

CD3 (T-cell surface glycoprotein CD3)pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on MDG3020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDG3020.

Explore the full profile